PROSTVAC-VF immunotherapy, based on prostate-specific antigen (PSA)-targeted poxviral vaccines for PCa, was well tolerated and related to a 44% decrease in mortality and an 8.5-month improvement for median OS among men with mCRPC in a phase II trial (42). This evidence concerns the gene KLK3 and posterior cortical atrophy.